Skip to main
  1. Stocks
  2. Mereo Biopharma Group Plc - ADR
  3. Forecast
MREO

MREO Stock Forecast & Price Target

MREO Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Mereo BioPharma Group is attractive because setrusumab still shows clinically meaningful fracture and bone mineral density benefits in higher-risk OI patients, and the FDA has signaled openness to alternative fracture analyses that could support a BLA despite the primary endpoint miss. The alvelestat program adds a second value driver in a large unmet-need AATD-LD market, with Sentynl potentially funding development through a $40M upfront/R&D payment, up to $435M in milestones, and double-digit U.S. royalties while Mereo retains ex-U.S. rights. Financially, the company ended 3Q26 with $26.1M in cash and equivalents, guiding runway into late 2027, while partnering activity and late-stage assets provide multiple near- and mid-term catalysts.

Bears say

Mereo BioPharma Group is viewed negatively because setrusumab failed to meet the trial’s key efficacy hurdles in Phase 3 ORBIT, with no statistically significant reduction in annualized fracture rates on either the primary endpoint or the all-fracture secondary endpoint, despite a 159-patient study. Although bone mineral density and some pain or daily activity measures improved, those benefits did not translate into the core clinical outcome needed to support a strong commercial case, especially in a rare disease setting where fracture reduction is critical. The company also remains financially constrained, since it will require additional funds to advance clinical candidates and there is no guarantee it can secure financing on favorable terms, receive milestone payments, or attract new partners.

MREO has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mereo Biopharma Group Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

MREO Analyst Forecast & Price Prediction

Get the latest MREO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MREO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mereo Biopharma Group Plc - ADR (MREO) Forecast

Analysts have given MREO a Buy based on their latest research and market trends.

According to 3 analysts, MREO has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mereo Biopharma Group Plc - ADR (MREO)


MREO Analyst Forecast & Price Prediction

Get the latest MREO stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MREO

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MREO stock data and trends